S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
NASDAQ:NLTX

Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis

$49.26
-0.19 (-0.38%)
(As of 03/27/2024 ET)
Today's Range
$48.62
$50.72
50-Day Range
$29.14
$49.88
52-Week Range
$2.03
$14.36
Volume
98,679 shs
Average Volume
50,104 shs
Market Capitalization
$462.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00
NLTX stock logo

About Neoleukin Therapeutics Stock (NASDAQ:NLTX)

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.

NLTX Stock Price History

NLTX Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Neurogene, Neoleukin Announce Planned Merger
See More Headlines
Receive NLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NLTX
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$30.00
Low Stock Price Target
$30.00
Potential Upside/Downside
-39.1%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-57,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.08 per share

Miscellaneous

Free Float
9,250,000
Market Cap
$462.95 million
Optionable
Optionable
Beta
1.11
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

NLTX Stock Analysis - Frequently Asked Questions

What is Neoleukin Therapeutics' stock price target for 2024?

0 Wall Street research analysts have issued 1-year price targets for Neoleukin Therapeutics' shares. Their NLTX share price targets range from $30.00 to $30.00. On average, they expect the company's share price to reach $30.00 in the next year. This suggests that the stock has a possible downside of 39.1%.
View analysts price targets for NLTX
or view top-rated stocks among Wall Street analysts.

How have NLTX shares performed in 2024?

Neoleukin Therapeutics' stock was trading at $19.38 at the beginning of 2024. Since then, NLTX stock has increased by 154.2% and is now trading at $49.26.
View the best growth stocks for 2024 here
.

How were Neoleukin Therapeutics' earnings last quarter?

Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) issued its quarterly earnings data on Thursday, November, 4th. The company reported ($5.60) earnings per share for the quarter, meeting analysts' consensus estimates of ($5.60).

When did Neoleukin Therapeutics' stock split?

Shares of Neoleukin Therapeutics reverse split before market open on Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

What other stocks do shareholders of Neoleukin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), RTX (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD).

Who are Neoleukin Therapeutics' major shareholders?

Neoleukin Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Priti Patel and Sean Michael Smith.
View institutional ownership trends
.

How do I buy shares of Neoleukin Therapeutics?

Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NLTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners